Welcome To Outcomes Insights

Outcomes Insights, Inc. was founded in 2003.  We analyze observational data including national survey data, build health economic models to support reimbursement, build simulation models of population effectiveness, create software to facilitate the analysis of observational data, and work on other related projects (literature reviews, meta-analyses, indirect treatment comparisons, strategic plans) that support one of our initiatives above.   We are also collaborators in the Observational Health Data Science and Informatics (OHDSI) organization, where we work on open-source projects to improve the quality of observational data analysis.

Our Services

For every disease state, understanding what happens to patients over time is critical to communicating the value of a product for treating a disease (or it complications). For example, event rates are used in building models, treatment effects can be estimated in populations that were not included in clinical trials, and long-term costs of care can be estimated and compared against models for validation purposes. In particular, these kinds of analyses are critical for conducting comparative effectiveness research. Read More…
We specialize in analyzing SEER-Medicare data, not only for solid tumors but also for lymphoma and leukemia (and eventually, myeloma). We have published our SEER Medicare work in a variety of journals, including Blood, BMC Cancer, Annals of Oncology, American Journal of Hematology, and Pharmacoeconomics.
Population effectiveness models are a relatively new concept, although the paradigm for constructing them has been around as long as health economics modeling. This model simulates relevant clinical outcomes for a population of patients with the disease of interest. The model incorporates many of the model-building techniques used in Markov-based and Monte Carlo-based cost-effectiveness models.
We build cost effectiveness models that assess the value of interventions. These models compare a new intervention to a standard of care with respect to two key endpoints: (1) the benefits received and (2) the costs incurred. The output is commonly expressed as the incremental cost-effectiveness ratio (ICER), which is the difference in cost divided by the difference in benefit.
We build budget impact models that estimate the cost from incorporating a new therapy into a health plan or system. These models are population-based, meaning that they incorporate incidence and prevalence rates for the population of interest. They generally compare a new therapy to the current standard of care, which could be one therapy or many.

We Specialize In

Mark DanesePresident
Mark Danese, MHS, PhD, has over 15 years of experience in epidemiology and outcomes research. He received his masters degree in Biostatistics in 1997, and his doctorate in Epidemiology in 1999, both from The Johns Hopkins University.
Quan DoanVice President
Quan Doan, MSHS, PharmD, has 8 years of experience in outcomes research consulting. His primary area of interest is the application of research design to inform drug policy decision making. This includes the appraisal of evidence, modeling of health care data, and evaluation of costs and outcomes.
Deborah LubeckVice President
Deborah Lubeck, Ph.D. has twenty-five years of experience in health economics and outcomes research. She has authored or coauthored over one hundred sixty peer-reviewed publications, and prepared a similar number of scientific meeting presentations.
Sherry DaneseVice President
Sherry has over 20 years of strategic and marketing consulting in the pharmaceutical and healthcare industry. She brings broad functional expertise, including strategic planning, product and franchise optimization, pipeline and in-line marketing, market research, forecasting, sales, sales operations, and regulatory affairs.